These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2870368)

  • 1. (+)-4-Propyl-9-hydroxynaphthoxazine in Parkinson's disease.
    Grandas Perez FJ; Jenner PG; Nomoto M; Stahl S; Quinn NP; Parkes JD; Critchley P; Marsden CD
    Lancet; 1986 Apr; 1(8486):906. PubMed ID: 2870368
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of levodopa with carbidopa, and levodopa with domperidone in Parkinson's disease.
    Langdon N; Malcolm PN; Parkes JD
    Clin Neuropharmacol; 1986; 9(5):440-7. PubMed ID: 3768866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The efficacy of (+)-4-propyl-9-hydroxynaphthoxazine as adjunctive therapy in Parkinson's disease.
    Weiner WJ; Factor SA; Sanchez-Ramos JR
    J Neurol Neurosurg Psychiatry; 1989 Jun; 52(6):732-5. PubMed ID: 2746265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.
    Coleman RJ; Quinn NP; Traub M; Marsden CD
    J Neurol Neurosurg Psychiatry; 1990 Feb; 53(2):102-5. PubMed ID: 1968963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained-release (+)-PHNO [MK-458 (HPMC)] in the treatment of Parkinson's disease: evidence for tolerance to a selective D2-receptor agonist administered as a long-acting formulation.
    Cedarbaum JM; Clark M; Toy LH; Green-Parsons A
    Mov Disord; 1990; 5(4):298-303. PubMed ID: 1979657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease.
    Diamond SG; Markham CH
    Adv Neurol; 1984; 40():537-9. PubMed ID: 6695633
    [No Abstract]   [Full Text] [Related]  

  • 7. Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.
    Ahlskog JE; Muenter MD; Bailey PA; Miller PM
    Clin Neuropharmacol; 1991 Jun; 14(3):214-27. PubMed ID: 1676932
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of artistic productivity in Parkinson's disease.
    Walker RH; Warwick R; Cercy SP
    Mov Disord; 2006 Feb; 21(2):285-6. PubMed ID: 16261619
    [No Abstract]   [Full Text] [Related]  

  • 9. The antiparkinsonian actions and pharmacokinetics of transdermal (+)-4-propyl-9-hydroxynaphthoxazine (+PHNO): preliminary results.
    Coleman RJ; Lange KW; Quinn NP; Loper AE; Bondi JV; Hichens M; Stahl SM; Marsden CD
    Mov Disord; 1989; 4(2):129-38. PubMed ID: 2733705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies in dopaminergic therapy of Parkinson's disease: the use of a controlled-release formulation. London, England, April 28 and 29, 1989. Proceedings.
    Neurology; 1989 Nov; 39(11 Suppl 2):1-106. PubMed ID: 2586761
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of carbidopa as an adjuvant to levodopa/carbidopa therapy in patients with Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Pasternack P
    N Y State J Med; 1986 Dec; 86(12):655-6. PubMed ID: 3468386
    [No Abstract]   [Full Text] [Related]  

  • 12. Carbidopa-levodopa ratio in Parkinson's disease.
    Weiner WJ; Nausieda PA
    Arch Neurol; 1981 Aug; 38(8):534. PubMed ID: 7247796
    [No Abstract]   [Full Text] [Related]  

  • 13. Sinemet in Parkinson's disease: efficacy with and without food.
    Bozek CB; Suchowersky O; Purves S; Calne S; Calne DB
    Clin Neuropharmacol; 1986; 9(2):196-9. PubMed ID: 3708604
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease.
    Busk K; Nyholm D
    Parkinsonism Relat Disord; 2012 Sep; 18(8):1000-1. PubMed ID: 22546333
    [No Abstract]   [Full Text] [Related]  

  • 15. Antiparkinsonian activity of a single oral dose of PHNO.
    Grandas F; Quinn N; Critchley P; Rohan A; Marsden CD; Stahl SM
    Mov Disord; 1987; 2(1):47-51. PubMed ID: 2904120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-dependent memory impairment in Parkinson's disease.
    Huber SJ; Shulman HG; Paulson GW; Shuttleworth EC
    Neurology; 1989 Mar; 39(3):438-40. PubMed ID: 2927659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease and motor fluctuations: long-acting carbidopa/levodopa (CR-4-Sinemet).
    Goetz CG; Tanner CM; Klawans HL; Shannon KM; Carroll VS
    Neurology; 1987 May; 37(5):875-8. PubMed ID: 3574696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release carbidopa-levodopa in Parkinson's disease.
    Rascol O
    Lancet Neurol; 2013 Apr; 12(4):325-6. PubMed ID: 23485609
    [No Abstract]   [Full Text] [Related]  

  • 19. Comment on: "Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review".
    Lambarth AT
    CNS Drugs; 2016 Oct; 30(10):1007-8. PubMed ID: 27541607
    [No Abstract]   [Full Text] [Related]  

  • 20. [Combined therapy of carbidopa and levodopa in Parkinson's disease].
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):201-4. PubMed ID: 4075908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.